Get the Stockscreener App
2.16
2.86%
0.06
Pre-market:
2.15
-0.01
-0.46%
Caribou Biosciences Inc stock is traded at $2.16, with a volume of 1.94M.
It is up +2.86% in the last 24 hours and up +1.41% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
See More
Previous Close:
$2.10
Open:
$2.1
24h Volume:
1.94M
Relative Volume:
1.33
Market Cap:
$214.23M
Revenue:
$11.16M
Net Income/Loss:
$-148.13M
P/E Ratio:
-1.3598
EPS:
-1.5885
Net Cash Flow:
$-112.35M
1W Performance:
+9.64%
1M Performance:
+1.41%
6M Performance:
+14.89%
1Y Performance:
+111.76%
1-Day Range:
$2.085
$2.2497
1-Week Range:
$1.88
$2.2497
52-Week Range:
$0.9573
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
2.16 | 208.28M | 11.16M | -148.13M | -112.35M | -1.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $11 - Moomoo
CRBU SEC FilingsCaribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
CRBU: Allogeneic CAR T programs show strong clinical progress and are advancing toward pivotal trials - TradingView
Caribou Biosciences stock (US1420381089): Q1 update and CRISPR pipeline stay in focus - AD HOC NEWS
CRBU Technical Analysis & Stock Price Forecast - Intellectia AI
Caribou Biosciences brings CMO and CFO to BioConnect Investor Conference fireside chat - Traders Union
CRBU Technical Analysis | Trend, Signals & Chart Patterns | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
Caribou Biosciences stock (US1420381089): fresh data from latest CAR?T update keeps investors watchi - AD HOC NEWS
Transcript : Caribou Biosciences, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 08 - marketscreener.com
Caribou Biosciences (CRBU) price target increased by 38.57% to 12.37 - MSN
Caribou Biosciences stock (US1420381089): Q1 earnings beat and 4.4% surge - AD HOC NEWS
May 2026's Promising Penny Stocks - Yahoo Finance
Bank of America Securities Remains a Buy on Caribou Biosciences (CRBU) - The Globe and Mail
BofA Securities Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference - Investing News Network
Caribou Biosciences attends BioConnect Investor Conference in New York next week - Traders Union
CRISPR biotech Caribou Biosciences plans H.C. Wainwright talk May 19 - Stock Titan
Need To Know: Analysts Are Much More Bullish On Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenues - simplywall.st
Industry Analysts Just Upgraded Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts By 30% - Moomoo
Industry Analysts Just Made A Massive Upgrade To Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts - Yahoo Finance
EHA2026 spotlights Caribou Biosciences advances in allogeneic CAR-T treatments for lymphoma and multiple myeloma - Traders Union
Caribou Biosciences, Inc. Announces Acceptance of Two Oral Presentations at the 2026 European Hematology Association Annual Meeting - Quiver Quantitative
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting - The Manila Times
Caribou Biosciences CEO Rachel Haurwitz to join Bank of America conference fireside chat - Traders Union
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Q4 EPS Forecast for Caribou Biosciences Lowered by Analyst - MarketBeat
MSN Money - MSN
Caribou Biosciences (NASDAQ:CRBU) Issues Quarterly Earnings Results - MarketBeat
Caribou Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Caribou Biosciences 報告了2026年第一季度的財務業績並提供了業務更新。 - Moomoo
RBC Capital Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Why Caribou Bio (CRBU) might surprise investors this quarter (Smart Money Flows) 2026-05-08AI Expert Picks - Newser
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Caribou Biosciences, Inc. (CRBU) reports Q1 loss, misses revenue estimates - MSN
Caribou Biosciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Caribou Biosciences (NASDAQ: CRBU) trims Q1 2026 loss, holds $118.6M cash - Stock Titan
Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Caribou secures FDA alignment on phase 3 trial, sees cash into 2H 2027 - Stock Titan
Caribou Biosciences (NASDAQ: CRBU) trims Q1 loss, holds $118.6M cash - Stock Titan
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference - The Manila Times
Caribou Biosciences to participate in BofA Securities Health Care event in Las Vegas - Traders Union
Caribou Biosciences (CRBU) price target decreased by 22.79% to 8.92 - MSN
Caribou Biosciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Caribou Biosciences (CRBU) corrects record‑date shares, June 17 virtual annual meeting - Stock Titan
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):